2. Academic Validation
  3. Breast cancer

Breast cancer

  • Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2.
Nadia Harbeck 1,  Frédérique Penault-Llorca 2,  Javier Cortes 3 4,  Michael Gnant 5,  Nehmat Houssami 6,  Philip Poortmans 7 8,  Kathryn Ruddy 9,  Janice Tsang 10,  Fatima Cardoso 11
Affiliations

Affiliations

  • 1 LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Breast Center and Comprehensive Cancer Center (CCLMU), Munich, Germany. nadia.harbeck@med.uni-muenchen.de.
  • 2 Department of Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, UMR INSERM 1240, University Clermont Auvergne, Clermont-Ferrand, France.
  • 3 IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain.
  • 4 Vall d´Hebron Institute of Oncology, Barcelona, Spain.
  • 5 Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • 6 Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • 7 Department of Radiation Oncology, Institut Curie, Paris, France.
  • 8 Université PSL, Paris, France.
  • 9 Department of Oncology, Mayo Clinic, Rochester, MN, USA.
  • 10 Hong Kong Breast Oncology Group, The University of Hong Kong, Hong Kong, China.
  • 11 Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
PMID: 31548545 DOI: 10.1038/s41572-019-0111-2
Abstract

Breast Cancer is the most frequent malignancy in women worldwide and is curable in ~70-80% of patients with early-stage, non-metastatic disease. Advanced breast Cancer with distant organ metastases is considered incurable with currently available therapies. On the molecular level, breast Cancer is a heterogeneous disease; molecular features include activation of human epidermal growth factor receptor 2 (HER2, encoded by ERBB2), activation of hormone receptors (oestrogen receptor and Progesterone Receptor) and/or BRCA mutations. Treatment strategies differ according to molecular subtype. Management of breast Cancer is multidisciplinary; it includes locoregional (surgery and radiation therapy) and systemic therapy approaches. Systemic therapies include endocrine therapy for hormone receptor-positive disease, chemotherapy, anti-HER2 therapy for HER2-positive disease, bone stabilizing agents, poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and, quite recently, immunotherapy. Future therapeutic concepts in breast Cancer aim at individualization of therapy as well as at treatment de-escalation and escalation based on tumour biology and early therapy response. Next to further treatment innovations, equal worldwide access to therapeutic advances remains the global challenge in breast Cancer care for the future.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z